Who makes Sham ITM + Usual Care?

Sham ITM + Usual Care is developed by First Affiliated Hospital, Sun Yat-Sen University.

What development phase is Sham ITM + Usual Care in?

Sham ITM + Usual Care is FDA-approved (marketed).

Last reviewed 2026-04-22 · How we verify

Sham ITM + Usual Care

First Affiliated Hospital, Sun Yat-Sen University · FDA-approved active Small molecule

Sham ITM + Usual Care is a control arm combining placebo acupuncture intervention with standard medical management.

At a glance

Generic name	Sham ITM + Usual Care
Sponsor	First Affiliated Hospital, Sun Yat-Sen University
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

This is a sham (placebo) comparator used in clinical trials, not an active pharmaceutical agent. It consists of simulated acupuncture (Intradermal Therapy Microneedles or ITM) combined with routine clinical care, serving as a control to evaluate the efficacy of active ITM treatment against placebo and standard care alone.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery, a IMPACT-Scope Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sham ITM + Usual Care CI brief — competitive landscape report
Sham ITM + Usual Care updates RSS · CI watch RSS
First Affiliated Hospital, Sun Yat-Sen University portfolio CI